Founded: 1891 (as a U.S. subsidiary of Merck KGaA, became independent after WWI).
Headquarters: Rahway, New Jersey, United States.
CEO & Chairman (2025): Robert M. Davis.
Employees: ~70,000+ worldwide.
Global Presence: Operations in over 140 countries.
Annual Revenue (2024 est.): More than $60 billion.
Human Health (Pharmaceuticals & Vaccines)
Oncology (cancer medicines, esp. Keytruda – immunotherapy).
Vaccines (notably Gardasil for HPV, and Pneumovax for pneumonia).
Diabetes & cardiovascular drugs (e.g., Januvia).
Infectious diseases & immunology.
Animal Health
Vaccines, medicines, and services for livestock and companion animals.
Heavy R&D investments (over $15 billion annually).
Research in AI-driven drug discovery and oncology immunotherapies.
Corporate Social Responsibility: Vaccine access programs, partnerships with WHO, and global health initiatives.
Ticker Symbol: MRK (NYSE).
Known As: MSD (Merck Sharp & Dohme) outside U.S. & Canada.
Major Competitors: Pfizer, Johnson & Johnson, Novartis, Roche, Bristol Myers Squibb.